Jacques P Tremblay
Overview
Explore the profile of Jacques P Tremblay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
2407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bouchard C, Godbout K, Tremblay J
Med Sci (Paris)
. 2024 Oct;
40(10):748-756.
PMID: 39450960
Gene editing is an ever-evolving field and Prime editing technology is among the latest ones. It makes it possible to modify a gene using a Cas9 nickase that cuts a...
2.
BenDavid E, Ramezanian S, Lu Y, Rousseau J, Schroeder A, Lavertu M, et al.
Pharmaceuticals (Basel)
. 2024 Jun;
17(6).
PMID: 38931430
Prime editing shows potential as a precision genome editing technology, as well as the potential to advance the development of next-generation nanomedicine for addressing neurological disorders. However, turning in prime...
3.
Charrier M, Leroux I, Pichon J, Schleder C, Larcher T, Hamel A, et al.
J Neuropathol Exp Neurol
. 2024 May;
83(8):684-694.
PMID: 38752570
We previously reported that human muscle-derived stem cells (hMuStem cells) contribute to tissue repair after local administration into injured skeletal muscle or infarcted heart in immunodeficient rodent models. However, extrapolation...
4.
Godbout K, Rousseau J, Tremblay J
Cells
. 2024 Jan;
13(1).
PMID: 38201236
We report the first correction from prime editing a mutation in the gene, paving the way to gene therapies for RYR1-related myopathies. The gene codes for a calcium channel named...
5.
Lu Y, Godbout K, Lamothe G, Tremblay J
Mol Ther Nucleic Acids
. 2023 Oct;
34:102040.
PMID: 37842166
Therapeutic genome editing has the potential to cure diseases by directly correcting genetic mutations in tissues and cells. Recent progress in the CRISPR-Cas9 systems has led to breakthroughs in gene...
6.
Bouchard C, Tremblay J
J Clin Med
. 2023 Sep;
12(18).
PMID: 37762951
Dysferlinopathy is a disease caused by a dysferlin deficiency due to mutations in the gene. Dysferlin is a membrane protein in the sarcolemma and is involved in different functions, such...
7.
Bouchard C, Gerard C, Yanyabe S, Majeau N, Aloui M, Buisson G, et al.
Genes (Basel)
. 2023 Aug;
14(8).
PMID: 37628705
Friedreich ataxia (FRDA) is a progressive neurodegenerative disease caused by a GAA repeat in the intron 1 of the frataxin gene (FXN) leading to a lower expression of the frataxin...
8.
Happi Mbakam C, Tremblay J
Expert Rev Neurother
. 2023 Aug;
23(10):905-920.
PMID: 37602688
Introduction: Duchenne muscular dystrophy (DMD) is one of the most severe and devastating neuromuscular hereditary diseases with a male newborn incidence of 20 000 cases each year. The disease caused...
9.
Bouchard C, Tremblay J
J Clin Med
. 2023 Jul;
12(14).
PMID: 37510884
Limb-girdle muscular dystrophies (LGMDs) are caused by mutations in multiple genes. This review article presents 39 genes associated with LGMDs. Some forms are inherited in a dominant fashion, while for...
10.
Lamothe G, Carbonneau J, Joly Beauparlant C, Vincent T, Quessy P, Guedon A, et al.
CRISPR J
. 2023 Jun;
6(4):369-385.
PMID: 37347931
The worldwide proliferation of the SARS-CoV-2 virus in the past 3 years has allowed the virus to accumulate numerous mutations. Dangerous lineages have emerged one after another, each leading to...